HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 321 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,009,634 | -16.3% | 265,578 | -2.8% | 0.23% | -6.1% |
| Q2 2023 | $11,956,787 | +11.2% | 273,298 | -2.9% | 0.24% | +11.9% |
| Q1 2023 | $10,748,461 | -33.7% | 281,447 | -1.2% | 0.22% | -34.1% |
| Q4 2022 | $16,201,934 | +36.8% | 284,744 | -4.9% | 0.33% | +34.6% |
| Q3 2022 | $11,843,000 | -10.1% | 299,528 | +0.0% | 0.25% | -5.7% |
| Q2 2022 | $13,175,000 | +13.3% | 299,434 | +2.7% | 0.26% | +40.3% |
| Q1 2022 | $11,626,000 | -0.9% | 291,520 | -0.1% | 0.19% | +9.4% |
| Q4 2021 | $11,737,000 | -3.3% | 291,899 | -2.2% | 0.17% | -6.1% |
| Q3 2021 | $12,141,000 | -13.9% | 298,454 | -3.9% | 0.18% | -13.8% |
| Q2 2021 | $14,109,000 | +0.5% | 310,692 | -7.7% | 0.21% | -0.5% |
| Q1 2021 | $14,039,000 | +8.7% | 336,754 | +11.3% | 0.21% | -11.0% |
| Q4 2020 | $12,920,000 | +67.3% | 302,503 | +2.9% | 0.24% | +38.6% |
| Q3 2020 | $7,724,000 | +20.4% | 293,903 | +22.9% | 0.17% | +11.8% |
| Q2 2020 | $6,413,000 | – | 239,194 | – | 0.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |